CompletedNot Applicable

The Efficacy and Mechanism of SMA+M1 Repetitive Transcranial Magnetic Stimulation on Freezing of Gait in PD

China64 participantsStarted 2024-10-08

Plain-language summary

This study is a double-blinded randomized study examining the efficacy of the double-site (M1+SMA) repetitive transcranial magnetic stimulation on Freezing of Gait (FOG) in patients with Parkinson's disease. The investigators hypothesize that treatment using magnetic stimulation on double site (including M1-LL and SMA) will improve FOG and gait symptoms in patients with Parkinson's disease.

Who can participate

Age range40 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. aged between 40-80 years;
✓. diagnosis of idiopathic Parkinson's disease (PD) according to the Movement Disorder Society clinical diagnostic criteria;
✓. patients were stable on dopaminergic treatment for at least 3 months;
✓. Item 3 of the Freezing of Gait Questionnaire(FOG-Q) scored ≥1;
✓. Patients experienced FOG during an interview.

Exclusion criteria

✕. comorbidities of major neurologic diseases other than PD;
✕. suffer from musculoskeletal disorders that could have interfered with their ability to walk;
✕. presence of contraindications for transcranial magnetic stimulation (TMS) and magnetic resonance imaging (MRI);
✕. marked tremor interfered with TMS detection;
✕. previously receiving any kinds of TMS interventions;
✕. severe cognitive impairment making cooperation impossible \[Mini Mental State Examination (MMSE) \< 24\];
✕. were unable to walk independently during the OFF state.

What they're measuring

Changes of Freezing of Gait severity

Timeframe: Assessed at baseline, one day post intervention, one month post intervention

Trial details

NCT IDNCT06415682

SponsorThe First Affiliated Hospital with Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-21

View on ClinicalTrials.gov More Parkinson Disease trials